Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort

[1]  V. Wong,et al.  Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. , 2021, The Journal of infectious diseases.

[2]  J. Borghi,et al.  Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.

[3]  M. Buti,et al.  Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. , 2020, Journal of hepatology.

[4]  Siddharth Singh,et al.  Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis , 2020, Hepatology.

[5]  J. Kao,et al.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy , 2020, Clinical Microbiology Reviews.

[6]  Y. Tse,et al.  Tenofovir is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. , 2019, Gastroenterology.

[7]  M. N. Kim,et al.  A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea. , 2019, Journal of hepatology.

[8]  R. Bruno,et al.  Update of the statements on biology and clinical impact of occult hepatitis b virus infection. , 2019, Journal of hepatology.

[9]  V. Wong,et al.  HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. , 2019, Journal of hepatology.

[10]  M. Buti,et al.  Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2019, Gastroenterology.

[11]  Yoshiyuki Suzuki,et al.  Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan , 2018, Journal of Gastroenterology.

[12]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[13]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[14]  A. Lok,et al.  Hepatitis B cure: From discovery to regulatory approval , 2017, Hepatology.

[15]  N. Chuaypen,et al.  Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  M. Yuen,et al.  Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. , 2017, Journal of hepatology.

[17]  John F. Flaherty,et al.  No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment , 2017, Journal of viral hepatitis.

[18]  M. Honda,et al.  Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. , 2016, The Journal of infectious diseases.

[19]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[20]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[21]  R. Mikolajczyk,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[22]  V. Wong,et al.  Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study , 2014, Gut.

[23]  H. Lee,et al.  HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability , 2013, Gut.

[24]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[25]  Chien-Jen Chen,et al.  Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Matthew Kowgier,et al.  Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. , 2010, Gastroenterology.

[27]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[28]  F. Zoulim,et al.  A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine , 2006, Journal of viral hepatitis.

[29]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[30]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[31]  Hyo Jeong Kim,et al.  Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study , 2019, JAMA oncology.

[32]  V. Wong,et al.  Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. , 2017, Journal of hepatology.

[33]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[34]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .